Novo Nordisk A/S - Form 6-K Filing

Novo Nordisk announced that the CHMP has recommended EU approval for Wegovy® 7.2 mg in a single-dose pen for obesity treatment. This follows positive results from the STEP UP trial, where Wegovy® 7.2 mg demonstrated an average weight loss of 20.7%. The company expects to launch this new dosage and delivery method in the EU in Q3 2026. Wegovy® 7.2 mg is already available in the US under the brand name Wegovy® HD and has shown significant weight reduction and a favorable safety profile comparable to previous semaglutide formulations. The filing also details the STEP UP and STEP UP T2D trials, the indications for Wegovy®, and provides information about Novo Nordisk, including its global presence and commitment to combating chronic diseases.